Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 2/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.42 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18486200 | 0.91 | TYMP (0.52) | TYMPSLC29A1ADORA3DNPH1ADORA2A | |
| SCHEMBL18486247 | 0.88 | TYMP (0.52) | TYMPSLC29A1ADORA3DNPH1 | |
| SCHEMBL18486406 | 0.88 | TYMP (0.52) | TYMPSLC29A1ADORA3DNPH1ADORA2A | |
| SCHEMBL18486296 | 0.88 | TYMP (0.56) | TYMPSLC29A1ADORA3DNPH1 | |
| SCHEMBL18486315 | 0.87 | TYMP (0.49) | TYMPSLC29A1ADORA3DNPH1ADORA2A | |
| SCHEMBL18486234 | 0.87 | TYMP (0.51) | TYMPSLC29A1ADORA3DNPH1ADORA2A | |
| SCHEMBL18486218 | 0.84 | TYMP (0.46) | TYMPSLC29A1ADORA3DNPH1 | |
| SCHEMBL18486345 | 0.84 | TYMP (0.34) | TYMPADORA3DNPH1 | |
| SCHEMBL18486386 | 0.82 | TYMP (0.52) | TYMPSLC29A1DNPH1ADORA2AADORA1 | |
| SCHEMBL18486278 | 0.82 | TYMP (0.56) | TYMPSLC29A1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3130597-B1 | OLIGONUCLEOTIDE HAVING A NON-NATURAL NUCLEOTIDE AT THE 5'-TERMINAL | KYOWA KIRIN CO LTD (JP) | 2021-11-10 | — | — | EP | disclosed |
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-07-09 | — | — | US | disclosed |
| US-20170354673-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | RNGTT, UPF1, NSUN3 | TYMP 120/4885SLC29A1 243/4885ADORA3 127/4885 |
| US-20170354673-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | RNGTT, UPF1, NSUN3 | TYMP 121/4885SLC29A1 253/4885ADORA3 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.